NDC 82449-500-01 - piperacillin and tazobactam
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 82449-500
- Requested NDC
- 82449-500-01
- Package NDCs from labels
- 82449-500-01, 82449-500-02
- Manufacturer
- Steriscience Specialties Private Limited | Steriscience Specialities Pte. Limited
- Effective date
- 2024-09-27
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| piperacillin and tazobactam - Steriscience Specialties Private Limited | Steriscience Specialities Pte. Limited | Steriscience Specialties Private Limited | Steriscience Specialities Pte. Limited | 2024-09-27 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Shandong Anxin Pharmaceutical Co., Ltd. | 420196a5-f62d-473f-84d8-d7fc3f31c3d3 | 2024-10-17 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM,TAZOBACTAM SODIUM | Fresenius Kabi USA, LLC | fc4d1e35-23eb-4654-8691-ae5bfd50a48a | 2024-10-16 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Fresenius Kabi USA, LLC | e53ebafc-3afa-4a1e-9313-fecd1c1c5d7c | 2024-10-16 | Boxed warning, Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM,TAZOBACTAM SODIUM | Fresenius Kabi USA, LLC | ba87ade3-4d41-40c0-9f6a-27e121a4136d | 2024-10-16 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Fresenius Kabi USA, LLC | 2cfa6723-175b-4c4d-8212-266844b07610 | 2024-10-16 | Boxed warning, Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Fresenius Kabi USA, LLC | c78e0931-ec79-58e5-8658-7fe692dc3b8b | 2024-10-16 | Boxed warning, Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Apotex Corp. | c18109cf-d5db-4cc1-83da-537c8ab0e05c | 2024-10-14 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Shandong Anxin Pharmaceutical Co., Ltd. | f817b9be-b12b-48ac-8e4e-57ef6812eb32 | 2024-10-14 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| piperacillin and tazobactam | PIPERACILLIN AND TAZOBACTAM | Armas Pharmaceuticals Inc. | 24d9b4f1-109c-4db4-8a99-03afff045b47 | 2024-09-27 | Warnings, Adverse reactions | ANDA065458 M98T69Q7HP UXA545ABTT |
| piperacillin and tazobactam | PIPERACILLIN AND TAZOBACTAM | Armas Pharmaceuticals Inc. | bbd1e6ae-e19a-4572-a0ec-e78c8aa31d2a | 2024-09-27 | Warnings, Adverse reactions | ANDA065458 M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM | Eugia US LLC | 80f4bdb8-131e-4485-b7a2-accd596d4cde | 2024-09-04 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin, Tazobactam | PIPERACILLIN SODIUM, TAZOBACTAM SODIUM | Sagent Pharmaceuticals | 83f4adcd-893c-4e9e-8f2b-e06299dcf34d | 2024-08-31 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Sandoz Inc | b1cb1314-d3e0-4b44-a1df-de14c32e8cc6 | 2024-08-23 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Hospira, Inc | 5e8bbfcd-3618-43ed-a158-9d524426fdc5 | 2024-08-23 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Zosyn in Galaxy Containers | TAZOBACTAM SODIUM AND PIPERACILLIN SODIUM | Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. | 8ab9d90d-2f7f-4599-a44f-3d0a8f8ab623 | 2023-03-15 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Fresenius Kabi USA, LLC | dc8208ea-a632-4291-a90b-2eba9a33bb40 | 2022-10-27 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Fresenius Kabi USA, LLC | b9bd733c-1176-42cb-b318-1223b7e48dcb | 2021-05-19 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
| Piperacillin and Tazobactam | PIPERACILLIN AND TAZOBACTAM | Fresenius Kabi USA, LLC | 1eb40c84-0cb3-4648-a39f-f4ebc4dbcb16 | 2021-04-02 | Warnings, Adverse reactions | M98T69Q7HP UXA545ABTT |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.